About this Journal Submit a Manuscript Table of Contents
ISRN Veterinary Science
Volume 2012 (2012), Article ID 862104, 6 pages
http://dx.doi.org/10.5402/2012/862104
Research Article

Nephroprotective Effect of POLYCAN on Acute Renal Failure Induced by Cisplatin in Rats

1Department of Anatomy and Histology, College of Oriental Medicine, Daegu Haany University, 290 Yugok-dong, Gyeongsan, Gyeongsangbuk-do 712-715, Republic of Korea
2The Medical Research Center for Globalization of Herbal Formulation, Daegu Hanny University, 290 Yugok-dong, Gyeongsan, Gyeongsangbuk-do 712-715, Republic of Korea
3Department of Veterinary Internal Medicine, College of Veterinary Medicine, Kyungpook National University, Daegu 702-701, Republic of Korea
4Glucan Corporation and Marine Bio-Industry Development Center, Hoenggye-ri 27 Ilgwang-myeon Gijan-gun, Busan 619-912, Republic of Korea
5Department of Veterinary Surgery, College of Veterinary Medicine, Kyungpook National University, Daegu 702-701, Republic of Korea

Received 9 December 2011; Accepted 31 January 2012

Academic Editor: R. Thanawongnuwech

Copyright © 2012 Sae-Kwang Ku et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

We performed to evaluate the effect of POLYCAN (β-glucan) on cisplatin-(CDDP-)induced acute renal failure (ARF) in rats. POLYCAN was administered orally once a day for 32 days. Each of 8 rats per group was selected based on the body weight (BW) after acclimatization and they were sacrificed at 5 days after CDDP injection. There was significant ( 𝑃 < 0 . 0 5 ) increase of BW after CDDP dosing in all POLYCAN groups than vehicle control and significant ( 𝑃 < 0 . 0 1 or 𝑃 < 0 . 0 5 ) decrease of absolute and relative kidney weight were detected in all POLYCAN groups compared with vehicle control. In addition, serum BUN and creatinine level in all POLYCAN groups were significantly ( 𝑃 < 0 . 0 1 or 𝑃 < 0 . 0 5 ) lower than vehicle control and the percentage of degenerative regions significantly ( 𝑃 < 0 . 0 1 ) decreased in all POLYCAN groups. As the results of CDDP-induced ARF process, dramatic decrease of the BW, increase of the kidney weight, serum BUN, and creatinine level were detected in vehicle control group compared with sham control group. The changes by CDDP-induced ARF process in POLYCAN groups were significantly and dose-dependently improved compared with vehicle control group. Therefore, POLYCAN has enough potential to develop as a new agent of prevention or treatment for ARF.